|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.26 - 07:33
|
Inbank unaudited financial results for Q1 2026 (GlobeNewswire EN)
|
|
|
Inbank started 2026 with strong sales growth and stable underlying performance, while profitability development was more moderate. In Q1 2026 Inbank earned a consolidated net profit of €4 million, decreasing 11% year-on-year. The return on equity (ROE) in Q1 was 9.4%....
|
|
|
|
|
|
|
|
|
30.04.26 - 07:03
|
CREDIT AGRICOLE SA: First quarter 2026 results - ROBUST RESULTS DESPITE MARKET TURBULENCE (GlobeNewswire EN)
|
|
|
At the meeting of the Board of Directors of Crédit Agricole S.A. on 29 April 2026, SAS Rue La Boétie informed the company of its intention to purchase Crédit Agricole S.A. shares on the market for a maximum amount of 800 million euros with no intention to increase its stake beyond 65% of the share capital of Crédit Agricole S.A. Details of the transaction are provided in a press release issued today by SAS Rue La Boétie....
|
|
|
|
|
|
|
|
|
|
|
30.04.26 - 07:03
|
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 (GlobeNewswire EN)
|
|
|
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held 3rd to 7th of May in Denver, Colorado, USA. The data being presented emphasise Roche's focus on preserving vision through innovative therapies, including Vabysmo® (faricimab), Susvimo® (Port Delivery Platform with ranibizumab) and the investigational interleukin-6 (IL-6) inhibitor, vamikibart. The data cover five retinal conditions including geographic atrophy (GA), retinal vein occlusion (RVO) and uveitic macular edema (UME) as well as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD)....
|
|
|
|